Clinical Trials Logo

Radiotherapy clinical trials

View clinical trials related to Radiotherapy.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 3

NCT ID: NCT03597984 Not yet recruiting - Radiotherapy Clinical Trials

Reduction of Pain Symptoms With Stereotactic Radiotherapy on Bone Metastases

PREST
Start date: July 1, 2019
Phase: N/A
Study type: Interventional

Interventional study without medicinal, randomized 1: 1 open-label, multicenter, phase 3 to evaluate the response in terms of reduction of pain symptomatology from bone metastases, comparing the conformational radiotherapy (3D-CRT) administered in conventional fractionation vs. extracranial stereotactic radiotherapy (SBRT) administered with concomitant integrated simultaneous boost (Simultaneous Integrated Boost-SIB)

NCT ID: NCT03554135 Not yet recruiting - Radiotherapy Clinical Trials

Single frActIoN eighT Gray Palliative Radiotherapy With Modulated Intensity for Pain Reduction

SAINT
Start date: December 1, 2018
Phase:
Study type: Observational [Patient Registry]

Non-randomized, monocentric, observational study to evaluate the response in terms of reduction of painful symptoms from bone metastases to radiotherapy with high personalization of treatment: performed with modern technology, supplied with modulated intensity technique with concomitant integrated boost, according to selection of patients in accordance with prognosis determined by specific prognostic score

NCT ID: NCT03144167 Not yet recruiting - Glioblastoma Clinical Trials

Study of Prognostic Biomarkers of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastomas in First Relapse After Failure of Radiochemotherapy

SPECTROBEVA
Start date: August 20, 2017
Phase: N/A
Study type: Interventional

No predictive factors are known for the response to the bevacizumab anti-angiogenic molecule (Avastin) given in the event of relapse of glioblastoma (GBM) following radiochemotherapy. Classical MRI with gadolinium injection and perfusion is not sufficient to predict survival and response or duration. We propose to evaluate the prognostic interest for 6-month survival of spectroscopic biomarkers of proliferation, glial reaction, infiltration and glutaminergic metabolism or glycolytic metabolism recorded at 7 and 28 days of application of the treatment. These biomarkers are based on the increase of an index combining choline / Creatine (Cho / Cr), Glx / Cr (Glutamine and glutamate / Creatine), NAA / Cr (N acetyl aspartate / Creatine) and lactate / Cr ratios. The long-term objective is to predict the survival of these relapsed GBM patients at an early stage and to identify responder patients who would benefit from this expensive molecule and avoid using it in non-responding patients

NCT ID: NCT03142282 Not yet recruiting - Clinical trials for Metastatic Colorectal Cancer

Consolidative Radiotherapy Plus Maintenance Chemotherapy for Metastatic Colorectal Cancer

MCRC-LC1
Start date: January 1, 2019
Phase: Phase 2
Study type: Interventional

This study is a randomized phase II trial of maintenance chemotherapy versus consolidative radiotherapy plus maintenance chemotherapy for patients with unresectable metastatic colorectal cancer (MCRC).

NCT ID: NCT00457210 Not yet recruiting - Quality of Life Clinical Trials

The Influence of Radiotherapy on Cognitive Function

Start date: April 2007
Phase: N/A
Study type: Observational

The cognitive function of 150 patients that undergone any Radiotherapy treatment to the brain will be assessed at 3 time points before and after the treatment.